XORTX Therapeutics Files 6-K Report
Ticker: XRTX · Form: 6-K · Filed: May 20, 2024 · CIK: 1729214
Sentiment: neutral
Topics: sec-filing, 6-k, routine-report
TL;DR
XORTX files routine 6-K, CEO signed off. Nothing major.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on May 17, 2024, to report its activities for the month of May 2024. The filing confirms that the company is a foreign private issuer and will file annual reports under Form 20-F. Allen Davidoff, the Chief Executive Officer, signed the report.
Why It Matters
This filing provides routine updates from XORTX Therapeutics Inc. as a foreign private issuer, indicating ongoing compliance and reporting activities.
Risk Assessment
Risk Level: low — This is a routine filing by a foreign private issuer and does not contain new financial information or significant operational updates.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes public in its home country, files with a stock exchange, or distributes to its security holders.
What does it mean that XORTX Therapeutics Inc. is a 'foreign private issuer'?
It means XORTX Therapeutics Inc. is a foreign entity that is not a U.S. government entity and meets certain other criteria, allowing it to file under different SEC rules, such as using Form 20-F for its annual reports.
What is the significance of the filing date and period?
The filing date is May 17, 2024, and it reports on activities for the month of May 2024, indicating the company is providing timely updates as required.
Who signed the Form 6-K filing on behalf of XORTX Therapeutics Inc.?
The filing was signed by Allen Davidoff, the Chief Executive Officer of XORTX Therapeutics Inc.
Does this filing indicate any new financial results or material events?
No, this Form 6-K appears to be a routine report of foreign private issuer activities and does not disclose specific financial results or material events.
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2024-05-17 19:00:14
Filing Documents
- f6k_051724.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-24-002957.txt ( ) — 12KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: May 17, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News release dated May 17, 2024